Src: a potential target for the treatment of triple-negative breast cancer (Q39584882)

13 September 2017

title

Src: a potential target for the treatment of triple-negative breast cancer (English)

1 reference

13 September 2017

1 reference

D Tryfonopoulos

1

1 reference

13 September 2017

S Walsh

2

1 reference

13 September 2017

D M Collins

3

1 reference

13 September 2017

L Flanagan

4

1 reference

13 September 2017

C Quinn

5

1 reference

13 September 2017

B Corkery

6

1 reference

13 September 2017

E W McDermott

7

1 reference

13 September 2017

D Evoy

8

1 reference

13 September 2017

A Pierce

9

1 reference

13 September 2017

N O'Donovan

10

1 reference

13 September 2017

J Crown

11

1 reference

13 September 2017

M J Duffy

12

1 reference

13 September 2017

publication date

28 February 2011

1 reference

13 September 2017

1 reference

13 September 2017

volume

22

1 reference

13 September 2017

issue

10

1 reference

13 September 2017

page(s)

2234-2240

1 reference

Triple-negative breast cancer--current status and future directions

13 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ757

Personalized cancer therapy with selective kinase inhibitors: an emerging paradigm in medical oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ757

Src kinases as therapeutic targets for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ757

The role of Src in solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ757

Targeting Src in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ757

Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ757

Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ757

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ757

Phosphorylated c-Src in the nucleus is associated with improved patient outcome in ER-positive breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ757

Is expression or activation of Src kinase associated with cancer-specific survival in ER-, PR- and HER2-negative breast cancer patients?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ757

RhoB and actin polymerization coordinate Src activation with endosome-mediated delivery to the membrane

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ757

Endosomal trafficking of Src tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ757

Translocation of Src kinase to the cell periphery is mediated by the actin cytoskeleton under the control of the Rho family of small G proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ757

Numb protein expression correlates with a basal-like phenotype and cancer stem cell markers in primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ757

Src inhibitor dasatinib inhibits growth of breast cancer cells by modulating EGFR signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ757

Dasatinib synergizes with doxorubicin to block growth, migration, and invasion of breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ757

Effects of Src kinase inhibition induced by dasatinib in non-small cell lung cancer cell lines treated with cisplatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ757

Identification of potential biomarkers for measuring inhibition of Src kinase activity in colon cancer cells following treatment with dasatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ757

Activity of the multikinase inhibitor dasatinib against ovarian cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ757

Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ757

Development of candidate genomic markers to select breast cancer patients for dasatinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ757

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDQ757

1 reference

13 September 2017

1 reference